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AbstrAct
Histone deacetylases (HDACs) are enzymes that regulate gene expression by 
modifying chromatin structure through removal of acetyl groups from target histones 
or non-histone proteins. Previous in vitro studies suggest that HDACs may be novel 
pharmacological targets in immune-mediated islet β-cell destruction. However, the 
role of specific HDAC in islet β-cell development and function remain unclear. Here, we 
generated a conditional islet β-cells specific HDAC3 deletion mouse model to determine 
the consequences of HDAC3 depletion on islet β-cell differentiation, maintenance and 
function. Islet morphology, insulin secretion, glucose tolerance, and multiple low-
dose streptozotocin (STZ)-induced diabetes incidence were evaluated and compared 
between HDAC3 knockout and wild type littermate controls. Mice with β-cell-specific 
HDAC3 deletion displayed decreased pancreatic insulin content, disrupted glucose-
stimulated insulin secretion, with intermittent spontaneous diabetes and dramatically 
enhanced susceptibility to STZ-induced diabetes. Furthermore, islet β-cell line, 
MIN6 cells with siRNA-mediated HDAC3 silence, showed decreased insulin gene 
transcription, which was mediated, at least partially, through the upregulation of 
suppressors of cytokine signaling 3 (SOCS3). These results indicate the critical role 
of HDAC3 in normal β-cell differentiation, maintenance and function.
INtrODUctION
 Diabetes mellitus is a group of multi-factorial 
metabolic diseases characterized by absolute or relative 
deficiencies in insulin production. Molecular mechanisms 
affecting pancreatic β-cell differentiation, proliferation, 
survival, and function are fundamental for understanding 
the pathogenesis of both type 1 and type 2 diabetes. 
Preserving a functional β-cell mass and promoting the 
β-cell differentiation, proliferation and function are 
therefore the primary targets of novel treatments aimed at 
curing and preventing diabetes mellitus.
 Histone deacetylases (HDACs) are enzymatic 
components of large multi-protein complexes that remove 
acetyl groups from lysine side chains of histones and other 
proteins. They contribute to epigenetic programming 
and regulation of gene expression during development 
and throughout life. Gene transcription is modulated by 
acetylation and deacetylation of histones. Acetylation 
of histones generally contributes to the formation of a 
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transcriptionally competent environment by relaxing the 
chromatin structure, allowing transcription factors to 
access the target DNA. In contrast, histone deacetylation 
compacts chromatin and leads to transcriptional repression 
[1] Recent studies also suggested that HDACs regulate the 
activity of a wide range of non-histone proteins [2], thus 
protein acetylation has a big impact in posttranslational 
regulation of proteins. 
 Mammalian HDACs are classified into four groups 
on the basis of their structure and function. HDAC3 is 
part of class I, which also includes HDAC1, 2, and 8 
[3]. Although class I HDACs are broadly expressed and 
structurally related, they have distinct developmental roles 
[4, 5]. All HDACs were found expressed in rat β-cell line, 
INS-1 cells, and rat islets, implying their potential roles 
in islet β-cell development and function [6]. Different 
HDACs participate in specific multiprotein repressive 
transcriptional complexes, which could potentially 
determine, at least in part, their unique functions. 
HDAC3 is a component of the nuclear receptor 
co-repressor complexes that contain N-CoR and SMRT 
[7]. Using cell specific HDAC3 deletion mouse models, 
previous studies have revealed the critical roles of HDAC3 
in cardiac functional maintenance and myocardial energy 
metabolism [8], liver metabolic homeostasis [9, 10], and in 
bone formation and bone marrow adipocyte differentiation 
[11]. Previous studies suggest that HDACs may be novel 
pharmacological targets in immune-mediated β-cell 
destruction leading to type-1 diabetes. HDAC inhibitors 
(HDACi) reduce cytokine induced β-cell toxicity and 
restore insulin secretion both in vitro and in vivo [6, 12-
14], in which class I HDACs, especially HDAC1 and 
HDAC3 may play essential role [13, 15]. However, the 
specific role of HDAC3 in islet β-cell development, 
differentiation, maintenance and function remain unclear. 
Here, we made a conditional islet β-cells specific HDAC3 
deletion mouse model to determine the consequences 
of HDAC3 depletion on islet β-cell differentiation, 
maintenance and function. 
rEsULts
Deletion of HDAC3 in islet β-cells in mice
 β-cell specific HDAC3 knockout mice (RIP-Cre+.
HDAC3fl/fl) were generated by mating mice expressing the 
Cre recombinase gene under the control of rat insulin 2 
gene promoter (RIP-Cre+) with HDAC3flox/flox mice [10] to 
obtain RIP-Cre+HDAC3fl/+ mice, which were then crossed 
with HDAC3fl/fl to get RIP-Cre+.HDAC3fl/fl knockout 
(KO) mice (Figure 1A). Littermates carrying HDAC3fl/
fl, without cre expression (RIP-Cre- HDAC3fl/fl) were used 
as wild type (WT) controls. Since RIP-Cre transgenic 
mice have been suggested to show glucose intolerance, 
heterozygous RIP-Cre+.HDAC3fl/+ (HET) mice were 
also used as control for glucose tolerance experiment. 
HDAC3flox/flox and RIP-Cre alleles were identified by PCR 
with related primers (Table S1) (Figure 1B). To confirm 
HDAC3 deletion in islet β-cells from RIP-Cre+ HDAC3fl/fl 
(HDAC3 KO) mice, dispersed islet cells from these mice 
and WT control littermates (RIP-Cre- HDAC3fl/fl) were 
co-stained for HDAC3 and insulin. As shown in Figure 
1C, insulin and HDAC3 co-expression was observed in 
dispersed WT β-cells, while none of the insulin expressing 
β-cells express HDAC3 in dispersed β-cells from HDAC3 
KO mice, indicating the efficient β-cells specific HDAC3 
deletion in these mice (Figure 1C). 
Spontaneous glucose metabolism features of RIP-
Cre+ HDAc3fl/fl mice
 Throughout the monitoring time (5 to 25 weeks of 
age), HDAC3 KO mice showed a moderately decreased 
body weight compared with the WT control littermates 
(Figure 2C). Meanwhile, HDAC3 KO mice displayed 
steady higher blood glucose levels, , starting at 6 weeks 
old, especially before 10 weeks old (Figure 2A and 2B). 
Fasting blood glucose levels were measured and compared 
between HDAC3 KO and WT control mice. All WT mice 
showed normal fasting glucose levels, while 2 out of 12 
HDAC3 KO mice showed elevated fasting glucose levels. 
Nevertheless, the overall fasting blood glucose level 
in HDAC3 KO group showed no significant difference 
comparing to that of WT control group (Figure 2 D).
Glucose intolerance and impaired glucose-
stimulated insulin secretion
 Glucose tolerance tests (GTT) was performed to 
assess the body’s response to glucose, including insulin 
secretion capacity. Male mice were i.p. injected with 
glucose of 1 or 2 g/kg of body weight, and impaired 
glucose clearance was observed in RIP-Cre+HDAC3fl/
fl mice at both doses compared to WT controls (Figure 
2E and 2F). Glucose tolerance in RIP-Cre+HDAC3fl/+ 
mice was indistinguishable from RIP-Cre-HDAC3flox/flox, 
indicating that glucose homeostasis was not affected by 
HDAC3 heterozygosity or RIP-Cre expression in β-cells. 
Insulin secretion following the glucose administration was 
measured. At 5 and 30 min post glucose injection, HDAC3 
KO mice showed impaired insulin secretion compared to 
WT controls which is consistent with increased glucose 
levels in the same animals (Figure 2F).
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Increased susceptibility to multiple low-dose 
streptozotocin (MLD-STZ)-induced diabetes
 To study the sensitivity of β-cell to toxicity and 
inflammation induced death, we set out to induce diabetes 
by MLD-STZ injections to animals. Blood glucose levels 
of HDAC3 KO mice showed dramatic increase compared 
to WT controls from day 8 till the end of the experiment 
(Figure 3A). When separating male and female mice into 
individual groups, the increased blood glucose levels in 
HDAC3 KO mice remained in both groups (Figure 3C 
and 3E). Consistent with different blood glucose levels, 
Figure 1: Generation of β-cell-specific HDAC3 knockout mice. A. The floxed and null alleles of HDAC3 as a result of 
recombination between LoxP sites. B. PCR results of genotyping from tail biopsies of RIP-Cre- HDAC3fl/fl (WT), RIP-Cre+ HDAC3fl/+ 
(HET) and RIP-Cre+ HDAC3fl/fl (KO) mice. C. Dispersed islet cells from WT and KO mice were immunostained for HDAC3 (red) and 
insulin (green). Yellow (merged) indicates coexpression of HDAC3 and insulin. (Scale bar, 20 µm).
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Figure 2: β-cell-specific deletion of HDAC3 causes higher blood glucose level, glucose intolerance and impaired insulin 
secretion in mice. A. Random blood glucose levels were monitored in WT (left) and KO (right) mice, each line represents an individual 
mouse. n = 6-7 male mice/group. B. The summary of non-fasting blood glucose levels and C. body weight monitored from 6- until 25-week 
of age. n = 6-7 male mice per group. The overall difference between KO and WT group was analyzed by ANOVA. D. Fasting blood glucose 
level was measured in 8- to 12-week-old KO and WT male mice. n = 8-12 male mice/group. Glucose tolerance test, 1g/kg body weight E. or 
2g/kg body weight F., was performed on 8- to 10-week-old KO and WT mice. n = 4-6 mice/group. G. Plasma insulin levels during glucose 
tolerance test at the dose of 2 g/kg body weight. n = 5-6 male mice/group. Data are presented as means ± SD. (*p < 0.05, ***p < 0.001).
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Figure 3: RIP-Cre+.HDAC3fl/fl mice are more susceptible to multiple low-dose STZ-induced (MLD-STZ) diabetes. 
Blood glucose levels throughout the MLD-STZ experiment were monitored and compared between KO and WT for all mice A., male mice 
C. or female mice E., respectively. Diabetes incidence was monitored and compared between KO and WT mice in all mice B., male mice 
D. or female mice F., respectively. Data are presented as means ± SD. (*p < 0.05, **p < 0.01).
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60% of the HDAC3 KO mice, while only 20% from WT 
controls developed diabetes by day15. By day25, more 
than 80% of HDAC3 KO mice, while only about 27% 
from WT controls developed diabetes (Figure 4B). Both 
male and female KO mice showed significant increased 
diabetes incidence compared to WT controls, respectively 
(Figure 3D and 3F). 
Decreased β-Cells and insulin content 
 Relative lower body weight, hyperglycemia, 
glucose intolerance, and dramatically increased sensitivity 
to STZ treatment in HDAC3 KO mice strongly suggest 
a developmental and/or functional defect in pancreatic 
islet β-cells. Histological analysis of pancreatic sections 
revealed no obvious malformation of islet structure, but 
Figure 4: Histopathological analysis of islets of β-cell-specific HDAC3 KO mice. Pancreatic sections were stained with 
hematoxylin and eosin from WT and KO mice without STZ treatment A. and B. or 25 days after STZ injection C. and D., scale bar, 100 
µm.). Islet area relative to total pancreas was evaluated and compared between KO and WT mice of untreated E., or 25 days after STZ 
treatment F.. n = 10-13 mice per group. Pancreatic insulin content was measure and compared between 8-12-week-old untreated KO and 
WT mice. n = 4-5 mice per group G.. The relative viability of Min6 cells transfected with non-targeting sequence siRNA or HDAC3-
specific siRNA was compared using MTT assay H.. (*p < 0.05, **p < 0.01).
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a trend of decreased overall islet area in HDAC3 KO 
mice was identified (Figure 4A, 4B and 4E p = 0.07). 
Meanwhile, HDAC3 KO mice showed significantly 
decreased pancreatic insulin content, in consistent with 
the trend of decreased islet β-cell mass (Figure 4G). To 
further evaluate the potential role of HDAC3 in β-cell 
viability, MTT assay was performed to compare the 
viability of Min-6 cells with HDAC3 silence or control, 
and no significant difference was identified (Figure 4H). 
Nevertheless, after STZ treatment, the histological islet 
β-cell mass decreased dramatically in HDAC3 KO mice, 
in consistent with their dramatically increased blood 
glucose level and diabetes incidence (Figure 4C, 4D 
and 4F; Figure 3). Taken together, these results strongly 
suggest that in addition to the potential involvement in 
islet β-cell development, HDAC3 also plays important 
roles in β-cell insulin secretion and homeostasis. 
Direct regulation of SOCS3 by HDAC3 in islet 
β-cells contributes to insulin production
 To investigate the potential molecular mechanisms 
involved in the insulin secretion defect of HDAC3 
depleted β-cells, Min6 cells were transfected with HDAC3 
siRNA. The expression of classical insulin relevant 
genes as well as genes involved in insulin secretory 
pathways and potentially regulated by HDAC3 was 
evaluated (Figure 5A). The mRNA level of SOCS3 was 
significantly increased in both HDAC3 silenced Min6 
cells and islets from RIP-Cre+ HDAC3fl/fl mice (Figure 5A 
& 5B). To explore the potential regulatory role of HDAC3 
on SOCS3, CHIP assay was performed to detect the 
potential binding of HDAC3 to the promoter of SOCS3. 
Immunoprecipitation of HDAC3 with anti-HDAC3 was 
able to robustly pull down the promoter of SOCS3 gene 
compared with rabbit IgG control antibody (Figure 5C). 
This result shows the direct binding of HDAC3 to SOCS3 
gene, indicating the direct regulatory role of HDAC3 on 
SOCS3 expression. To further confirm the regulatory role 
of HDAC3 and the involvement of SOCS3 in HDAC3 
deficiency induced β-cell dysfunction, Min6 cells were 
co-transfected with siRNAs against HDAC3 and SOCS3. 
Seventy-two hours after transfection, a flow cytometry 
analysis was performed to confirm the silence efficiency 
(Figure 5D). As expected, HDAC3 silence interrupted the 
transcription of both insulin1 and insulin2. In contrast, 
SOCS3 silence increased insulin transcription in Min6 
cells. Nevertheless, HDAC3 and SOCS3 co-silence 
reversed the inhibitory effect of HDAC3 silence on insulin 
transcription, but only insulin2 mRNA change reach the 
statistical significant level (Figure 5E). Furthermore, 
in agreement with the insulin mRNA changes, SOCS3 
silence elevate the insulin content, while the co-silence of 
SOCS3 and HDAC3 rescue the decreased insulin content 
and secretion induced by HDAC3 silence (Figure 5F & 
5G). 
DIscUssION
 HDAC3 is essential for embryonic development 
[4, 5]. It associates with numerous transcription factors, 
co-repressors, class II HDACs [7, 16, 17], and plays 
critical roles in multiple organ development, metabolic 
homeostasis and function [8, 11]. In the current study, we 
made mouse model with conditional deletion of HDAC3 
in islet β-cells to investigate the roles of HDAC3 in islet 
β-cell development and function [18, 19]. Mice with 
β-cell-specific HDAC3 deletion displayed decreased 
insulin content, disrupted glucose-stimulated insulin 
secretion and tolerance, and dramatically enhanced 
susceptibility to low dose STZ induced diabetes. These 
data strongly indicate the important role of HDAC3 in 
islet β-cell insulin secretion capacity and vulnerability 
of β-cells to toxic and inflammatory attack in addition 
to its potential involvement in β-cell differentiation. 
Furthermore, Min6 cells with siRNA mediated HDAC3 
silence showed decreased insulin gene transcription, which 
was mediated, at least partially, through up-regulation of 
SOCS3. These results not only confirm the critical role 
of HDAC3 in β-cell insulin secretion function, but also 
illuminate the potential molecular mechanisms of HDAC3 
mediated islet β-cell functional regulation. Together, 
studies from both in vivo and in vitro models indicate that 
HDAC3 is essential for proper islet β-cell differentiation, 
function and maintenance. 
 The roles of HDACs in pancreatic developmental 
regulation remain largely unknown. Class I and class II 
HDACs are expressed in the embryonic pancreas. The 
pancreatic expression of HDACs are developmentally 
regulated, with significantly decreased most class I and 
II HDAC expression upon differentiation [20], consistent 
with the regulated HDACs expression during osteogenesis 
and adipogenesis [21, 22]. In contrast to other HDACs, 
HDAC3 expression was dramatically up-regulated in 
adult pancreas compared to different embryonic stages, 
suggesting the potential role of HDAC3 in not only 
pancreatic development, cell differentiation but also their 
function and maintenance [20]. 
Treatment of rat embryonic explants with HDAC 
inhibitors (HDACi) ex vivo promoted the NGN3 pro-
endocrine lineage development, leading to an increased 
pool of endocrine progenitors. However, different HDACi 
showed opposing effects on the endocrine β/δ lineage 
differentiation, in which preferential Class I HDACi VPA/
MS275 induced a dramatic decrease in Pax4 and insulin 
expression, while the Class I and II HDACi TSA/NaB 
enhanced Pax4 and insulin expression, suggesting the 
specific roles of individual HDACs in the development and 
differentiation of pancreatic β-cells [20]. Consistent with 
these results, mice with β-cell specific HDAC3 deletion 
in our study showed decreased pancreatic insulin content, 
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Figure 5: SOCS3 upregulation by HDAC3 depletion in islet β-cells contributes to insulin production defect. A. Real-time 
PCR analysis of insulin related gene mRNA changes in HDAC3 silenced Min6 cells. B. Real-time PCR analysis of changed SOCS3 mRNA 
levels in HDAC3 KO and WT control mice. C. CHIP assays were performed with Min6 cells. Chromatin was immunoprecipitated with anti-
HDAC3 or rabbit IgG control antibody, and precipitated DNA was used as a template to detect the SOCS3 promoter. Nonimmunoprecipitated 
sample served as an input control. D. Flow cytometry analysis of Min6 cells with HDAC3 or SOCS3 silencing. E. Real-time PCR analysis 
of Insulin1 and Insulin2 mRNA levels in different siRNA transfected Min6 cells. Insulin content F. and glucose stimulated insulin secretion 
F. of Min6 cells with silenced HDAC3, SOCS3 or both. Data are presented as means ± SD. (*p < 0.05, **p < 0.01). 
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trend of decreased β-cell mass, moderate hyperglycemia, 
which could result, at least partially, from the interrupted 
β-cell linage differentiation induced by HDAC3 deletion. 
 HDAC3 is among the β-cell expressed HDACs 
down-regulated by inflammatory cytokine treatment 
of both primary β-cells and β-cell lines [6, 23]. Pan-
HDACi ITF2357 treatment dose-dependently reversed 
cytokine induced β-cell death and the impairment of 
insulin secretion in INS-1 cells and primary rat β-cells, 
respectively; whereas ITF2357 itself had no effect on 
primary rat β-cell insulin secretion and survival, except 
for high dose of ITF2357 showing a trend of promoting 
effects on INS-1 apoptosis [6]. Using individual HDAC 
deleted INS-1 cells or primary rat β-cells, a more recent 
study further confirmed that HDAC1 and HDAC3 
deletion can partially rescue cytokine-induced β-cell 
apoptosis. Nevertheless, the individual HDAC deletion 
itself had no effects on β-cell survival [15]. Multiple 
low dose-streptozotocin (MLD-STZ) induces diabetes 
through primary β-cell toxicity plus secondary local 
inflammation [24]. In the current study, mice with 
β-cell-specific HDAC3 deletion displayed significantly 
enhanced susceptibility to MLD-STZ treatment compared 
to littermate controls, which could result from either 
interrupted primary β-cell differentiation and function, 
or the increased sensitivity of β-cells to the toxicity 
of STZ and inflammatory factors, or both. This result 
is inconsistent with aforementioned protective role of 
HDACis in inflammatory cytokine mediated β-cell 
apoptosis and functional defects. Comparing these 
studies with our model system, there are a few possible 
explanations for the apparent discrepancies: first, Cre-
mediated recombination of HDAC3 in β-progenitor 
cells is a permanent event and the phenotypes may result 
from HDAC3 deletion-mediated β-cell development, 
differentiation as well as mature β-cell function and/or 
maintenance defects. In contrast, small molecule HDACis 
have short half-life in serum or culture medium and might 
only transiently change chromatin structure and gene 
expression in normally developed β-cells in relatively 
short-term assays. Second, HDACs participate in 
multiprotein transcriptional complexes. Genetic deletion 
of an HDAC perturbs the complexes in which it would 
normally be associated, whereas inhibitors are believed to 
block enzymatic activity without necessarily disrupting 
the repressive complex. Furthermore, striking difference 
exist in etiopathogenesis of β-cell destructions induced 
by cytokine treatment versus MLD-STZ which include 
primary β-cell toxicity from STZ plus secondary local 
inflammation [24]. 
 SOCS are intracellular proteins that control signals 
from cytokine receptors and are essential for immune 
physiology. SOCS proteins are induced by cytokines and 
act to inhibit cytokine signal transduction. SOCS3 has 
been reported to protect against cytokine mediated β-cell 
destruction by suppressing IFN-γ and IL-1β signaling 
in vitro [25, 26]. In mice, however, β-cell specific 
overexpression of SOCS3 failed to protect against MLD-
STZ induced diabetes [27]. Leptin-mediated SOCS3 up-
regulation transcriptionally inhibits preproinsulin gene 
expression in β-cells [28]. In addition to the impact of 
SOCS3 on β-cell insulin production, SOCS3 inhibits 
GH-mediated β-cell proliferation, and mice with SOCS3 
overexpression showed over 30% β-cell mass reduction 
[29]. However, mice with haploinsufficiency of SOCS3 
showed enhanced leptin sensitivity and were protected 
against the development of diet-induced obesity and 
associated metabolic complications [30]. Furthermore, 
elevated SOCS3 expression suppressed insulin signaling 
through inhibiting the phosphorylation of insulin 
receptor (IR) and insulin receptor substrates (IRS), while 
promoting the degradation of IRS1 and IRS2 [31-33] 
These results clearly demonstrate the essential role of 
SOCS3 in balancing islet β-cell mass, function and even 
insulin sensitivity. In the current study, siRNA silencing 
of HDAC3 dramatically upregulate SOCS3 expression in 
Min6 cells, in concord with interrupted insulin production, 
while SOCS3 silencing partially reverse the down 
regulation of insulin transcription. These results indicate 
the critical involvement of SOCS3 in HDAC3 deletion 
induced β-cell functional defects. Nevertheless, we cannot 
rule out the possibilities of the involvement of additional 
genes whose activation or expression is under the control 
of HDAC3. 
 HDAC3-containing N-CoR/SMRT complexes 
bind preferentially to hypoacetylated histones [34, 35]. 
However, class I HDACs not only remove acetyl groups 
from histones tails but can also deacetylate transcription 
factors and other chromatin-associated proteins. Thus, 
class I HDACs can affect gene transcription at different 
levels [36]. Recent studies have shown the evidence of 
HDAC mediated SOCS3 expression regulation: HDACi 
treatment can promote the SOCS1 and SOCS3 expression 
in human colorectal cancer and human leukemia through 
inducing the hyperacetylation of histones associated 
with the SOCS3 promoters [37, 38], which further 
suppress Janus kinase/signal transducers and activators 
of transcription (JAK/STAT) signaling involved in the 
oncogenesis of different cancers [39]. Thus, these results 
link SOCS proteins with the anti-tumor functions of 
HDACis, which further support our findings that SOCS3 is 
one of the major molecules involved in HDAC3-mediated 
islet β-cell differentiation, and function. In addition, our 
CHIP data suggested the direct regulatory role of HDAC3 
on SOCS3 expression. These data combined with previous 
identified hyper acetylated histone-associated SOCS3 
expression regulation indicate the existence of complex 
multi-pathways in HDAC mediated SOCS protein 
regulation including at least the conventional Histone 
deacetylation-mediated and the direct regulation pathway 
possibly recruited by SOCS3 regulatory transcription 
factors. The detailed molecular mechanisms of SOCS3-
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dependent and -independent pathways of HDAC3 related 
islet β-cell development, differentiation and functional 
regulation will be further investigated in future studies. 
 In summary, using the islet β-cell specific HDAC3 
deletion mouse model combined with HDAC3 silenced 
Min6 cell line, our results indicate the critical role of 
HDAC3 in islet β-cell differentiation, function and 
maintenance, and the role of SOCS3 in HDAC3 deletion 
induced β-cell dysfunction. These results not only 
provide further insight into the epigenetic mechanisms 
of β-cell development and functional regulation, but also 
emphasize the importance of understanding the role and 
mechanisms of individual HDACs in β-cell regulation, for 
future HDAC related clinical applications with increased 
specificity and minimized toxicity in the treatment and 
prevention of diabetes mellitus and other diseases.
MATERIALS AND METHODS
Islet isolation, dispersion, immunofluorescence 
staining, and pancreas histological and 
immunofluorescence analysis
 Mouse islets were isolated by type V collagenase 
(Sigma Chemicals, St Louis, MO, USA) digestion of 
pancreas. Isolated islets were exposed to 0.25% trypsin-
EDTA at 37°C for 10 min, followed by gently pipetting 
for 1-2 min to dissociate into single cells. Dispersed 
islets cells were fixed in 4% (vol./vol.) paraformaldehyde 
for 10 min, permeabilized with 0.25% (vol./vol.) Triton 
X-100 for 10 min and blocked overnight in 1% (wt/vol.) 
BSA at 4°C. Cells were then labeled overnight at 4°C 
with polyclonal anti-HDAC3 (Abcam, Cambridge, MA, 
USA) and monoclonal anti-insulin (Linco, Research, 
Inc., St Louis, MO, USA) antibodies. Cells were then 
stained at room temperature in dark for 60 min with PE-
conjugated goat anti-rabbit, FITC-conjugated goat anti-
mouse secondary antibodies (eBioscience, San Diego, CA, 
USA) respectively. Cells were washed and mounted on 
glass slides which were viewed on a microscope (Leica 
Microsystems, Wetzlar, Germany).
 Pancreases obtained from 8- to 12-week-old 
mice were used for morphometry and immunostaining. 
For histological analysis, pancreases were fixed in 10% 
formalin, paraffin-embedded, and sectioned in 6 μm 
(each section spaced at least 50 μm apart), 4 sections of 
each animal were used. Pancreas sections were stained 
with hematoxylin and eosin for histological study. To 
measure islet area, sections were photographed at low 
magnification. Images were imported to a software 
(ImageJ, NIH, Bethesda, MA, USA), and total pancreas 
and islet areas were selected. Pixel numbers in selected 
areas were used to calculate the relative islet area to total 
pancreas.
Glucose tolerance test
 Mice were subjected to glucose tolerance test at 
8-10 weeks of age. Mice were fasted overnight (16 hours) 
and intraperitoneally injected with 0.9% NaCl solution 
containing D-glucose at the dose of 1 or 2g/kg body 
weight. Blood samples for glucose measurements were 
taken at 0, 5, 10, 15, 30, 60 and 120 minutes after the 
glucose load. Serum was also collected at 0, 5, 30 minutes 
after glucose load, insulin concentration was detected 
using mouse insulin ELISA Kit (Crystal Chem Inc., 
Chicago, Illinois, USA)
Multiple low-dose streptozotocin (MLD-STZ) 
treatment
 Mice were intraperitoneal injected with STZ (Sigma 
Chemicals, St Louis, MO, USA) of 40 mg/kg body weight 
for five consecutive days. Blood glucose levels were 
measured twice a week using a glucometer (FreeStyle, 
Abbott, Alameda, CA, USA). Mice were considered 
diabetic when blood glucose levels were > 200 mg/dl in 
two consecutive measurements. Mice were killed on day 
25 of the study; pancreases and serum were collected and 
used for further evaluation.
Cell culture and RNA interference
 Min-6 cells were cultured in 25mmol/l glucose 
Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 15% fetal bovine serum, 50 µM 
β-mercaptoethanol, 100 units/ml penicillin, 100 μg/ml 
streptomycin, and 2 mmol/l l-glutamine at 37°C, 5% CO
2
. 
Cells were trypsinized, counted, and plated in culture 
medium without antibiotics at a density of ~ 40-50%, 
24 hours before transfection. The on-target HDAC3 and 
Suppressors of cytokine signaling 3 (SOCS3) siRNAs 
(Thermo Scientific, Lafayette, CO, USA) as well as non-
targeting sequence siRNA were transfected at a working 
concentration of 50 nM using Lipofectamine RNAiMax 
(Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s instruction. Transfected cells were cultured 
for 72 hrs for glucose-stimulated insulin secretion, 
flowcytometry analysis and Real-time PCR.
RNA isolation and quantitative real-time PCR
 Total RNAs were isolated using Qiazol (Qiagen, 
Valencia, CA, USA) and subjected to reverse transcription 
using High Capacity cDNA Reverse Transcription Kit 
((Applied Biosystems, Foster City, CA, USA). Real-
time PCR was performed in triplicates using FastStart 
Universal SYBR Green Master (Roche Diagnostics Corp., 
Indiana, USA) on ABI 7900 HT Real-Time PCR system 
Oncotarget57495www.impactjournals.com/oncotarget
(Applied Biosystems, Foster City, CA, USA). Data were 
normalized to mouse β-actin mRNA. 
Chromatin immunoprecipitation (CHIP) assay
 CHIP assays were performed using an EZ-CHIP 
kit (Millipore, Billerica, MA, USA), following the 
manufacturer’s instructions. CHIP-grade anti-HDAC3 
(Abcam, Cambridge, MA, USA), rabbit IgG negative 
control antibody (eBioscience, San Diego, CA, USA) 
and anti-RNA polymerase II (Millipore, Billerica, MA, 
USA) were used to immunoprecipitate the protein-DNA 
complexes. Purified immunoprecipitated DNA was 
analyzed by PCR with primers for SOCS3 promoter 
(Table S1). 
Glucose-stimulated insulin secretion and insulin 
content test
 The cultured cells were washed and pre-incubated 
for 60 min in Krebs-Ringer bicarbonate buffer (129.4 
mmol/l NaCl, 5.2 mmol/l KCl, 1.3 mmol/l KH
2
PO4 , 2.7 
mmol/l CaCl
2
, 1.3 mmol/l MgSO4 , 24.8 mmol/l NaHCO3, 
10 mmol/l HEPES, 0.1% BSA [pH 7.4]) with 2.8 mmol/L 
glucose. Upon completion of the incubation, the buffer 
was removed completely and replaced with fresh KRB 
containing 20 mmol/L glucose for an additional 45 min. 
The supernatant was collected for measuring insulin 
secretion.
The total insulin in the cells as well as the whole 
pancreas was extracted by acid ethanol (0.18 M HCl in 
95% ethanol) treatment overnight. Insulin concentration 
was measured using mouse insulin ELISA Kit (Crystal 
Chem Inc., Chicago, Illinois, USA). Insulin secretion and 
content were normalized to total protein.
Flow cytometry (FACS)
 Min-6 cells were trypsinized, washed twice with 
FACS staining buffer (PBS, 3% FBS), and then incubated 
with Fc block (clone 2.4G2). Trypsinized cells were first 
fixed and permeabilized by Foxp3 Fixation Buffer and 
Permeabilization Buffer (eBioscience), and then incubated 
with Fc blocker (clone 24G2). Treated cells were then 
stained with related antibodies: anti-HDAC3 (ab7030, 
Abcam), anti-SOCS3 (ab16030, Abcam), or rabbit IgG as 
isotype control, followed by incubation with FITC or PE-
conjugated anti-rabbit IgG (eBioscience, 1:100 dilution). 
Data was harvested by FACSAriaII Flow Cytometer 
(BD Biosciences) and analyzed using FlowJo software 
(FlowJo, LLC).
Statistical analysis
 Statistical analysis was performed with Prism 
5.0 (GraphPad Software, San Diego, CA). A two-tailed 
Student t test was used to test the differences between 
two groups. ANOVA was used to compare the means of 
multiple groups. Data are presented as mean ± standard 
deviation (SD). Gehan-Breslow-Wilcoxon test was used 
for the analysis of the incidence of diabetes. Differences 
were considered significant with a p value < 0.05.
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